Production (Stage)
Innate Pharma S.A.
IPHYF
$1.45
-$0.31-17.61%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.17M | -13.58M | -13.33M | -13.44M | -5.00M |
| Total Depreciation and Amortization | 454.10K | 468.30K | 614.60K | 619.90K | 778.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 723.80K | 746.50K | 32.80K | 33.10K | 166.90K |
| Change in Net Operating Assets | 6.70M | 6.91M | 14.31M | 14.44M | -7.30M |
| Cash from Operations | -5.29M | -5.46M | 1.63M | 1.65M | -11.35M |
| Capital Expenditure | -57.60K | -59.40K | -152.30K | -153.60K | -22.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 80.70K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.46M | 4.60M | 653.90K | 659.50K | 11.18M |
| Cash from Investing | 4.41M | 4.54M | 501.60K | 505.90K | 11.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.26M | -2.26M | -2.21M | -2.21M | -383.50K |
| Issuance of Common Stock | 1.42M | 1.42M | 46.50K | 46.50K | 23.50K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -895.90K | -924.00K | -2.33M | -2.35M | -387.60K |
| Foreign Exchange rate Adjustments | -132.20K | -136.30K | -138.30K | -139.50K | 69.40K |
| Miscellaneous Cash Flow Adjustments | -500.00 | -600.00 | 500.00 | 500.00 | 0.00 |
| Net Change in Cash | -1.92M | -1.98M | -331.00K | -333.80K | -435.50K |